Immunowake
PrivateLast Round
Early Funding
Nov 25, 2025
Total Funding Raised
$23M
Company Overview
Immunowake is a biotechnology company that develops cytokine-based agonists and bi-specific antibodies for the treatment of cancer and autoimmune diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Immunowake Comparables
Compare Immunowake with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Proviva Therapeutics | 81% | |
| Bright Peak Therapeutics | 78% | |
| Anaveon | 78% |
Immunowake Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Nov 25, 2025 | ||||
| Series A | May 1, 2022 | ||||
| Seed | Aug 22, 2019 |
Immunowake Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Heda Ventures | Series A |
| Lapam Capital | Series A |
| Hyfinity Investments | Series A |
| HEDA Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- May 1, 2022
$20M round led by Hyfinity Investments.
Immunowake Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Immunowake's valuation, stock price, and market status.
Is Immunowake a public or private company?
Immunowake is a private company.
What is the current stock price of Immunowake?
Immunowake is a private company with no public stock price. No recent secondary market data is available.
How much is Immunowake worth (valuation)?
Valuation information for Immunowake is not publicly available.
Can I buy Immunowake stock?
Immunowake shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Immunowake's last funding round?
Immunowake's most recent funding round was Series A on May 15, 2022.
Who are the main investors in Immunowake?
Key investors in Immunowake include Hyfinity Investments.
Will Immunowake IPO soon?
No public IPO plans have been announced for Immunowake.
How can I track Immunowake secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Immunowake's secondary market activity and sign up for updates.